MOUNTAIN VIEW, Calif., Sept. 7 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following healthcare conferences in September:
Morgan Stanley Global Healthcare Conference
Tuesday, September 14, at 11:30 a.m. ET in New York
Stifel Nicolaus 2010 Healthcare Conference
Wednesday, September 15, at 2:05 p.m. ET in Boston
UBS Global Life Sciences Conference
Tuesday, September 21, at 9:00 a.m. ET in New York
A live webcast of the events will be available on the Investor Relations section of MAP Pharmaceuticals’ website at http://www.mappharma.com. A replay will also be available within 24 hours following the presentation.
In addition, the Company will be presenting its LEVADEX orally inhaled migraine therapy Phase 3 data at the American Neurological Association’s 135th Annual Meeting on Monday, September 13, at 1:00 p.m. in San Francisco.
About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACTS: | |
Nicole Foderaro | |
WCG | |
(415) 946-1058 | |
nfoderaro@wcgworld.com | |
SOURCE MAP Pharmaceuticals, Inc.
